RWE Study Conducted by PEGUS Research Published in Contraception 
Results from a US Real-World Evidence (RWE) study conducted by PEGUS were recently published in…
John EvansJune 14, 2022
Latest News
Sterling IRB Features Pegus Research in Whitepaper Article Titled “PPC and Social Media Patient Recruitment: Strategies for Success”
The Sterling Institutional Review Board (IRB) featured PEGUS Research’s innovative and versatile marketing strategies in…
John EvansApril 12, 2022
MHRA Approves Nuromol (Combined Paracetamol and Ibuprofen) for General Sale in UK
On 16 August, 2021, the UK Medicine and Healthcare products Regulatory Agency (MHRA) made Nuromol,…
John EvansAugust 20, 2021
FDA Approves “First-in-Class” Nasal Antihistamine (Astepro Allergy) For OTC
On 17 June 2021, the US Food and Drug Administration (FDA) announced approval of a…
John EvansJune 21, 2021
Clark Richardson Participates in June 2021 FDA Public Workshop on the OTC Drug Facts Label
Clark Richardson, PEGUS President & CEO, participated in a 09 June 2021 FDA public workshop…
John EvansJune 14, 2021
PEGUS Announces Even More Enhancements to Its “Decentralized” Research Model
Innovating at Unprecedented Pace COVID-19 prompted dramatic changes in the way we conduct research. In…
John EvansFebruary 8, 2021
Brandon Henrie Promoted to Vice President – Finance and Strategy
We are pleased to announce Brandon Henrie has been promoted to Vice President – Finance…
John EvansFebruary 8, 2021
FDA Approves New Combination Pain Reliever (Advil Dual Action) for OTC
On 28 Feb. 2020, the US Food and Drug Administration (FDA) approved a novel fixed-dose…
John EvansMarch 5, 2020
